NR3C2 and diabetic kidney disease: Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist with higher receptor selectivity than spironolactone and better receptor affinity than eplerenone in vitro, provides cardiorenal and renal dual-protective effects in DKD patients (8).